New Non-Hodgkins Lymphoma Treatment Ready for Human Clinical Trials

InNexus Biotechnology Inc., located in Toronto Canada, said they are ready to move their treatment aimed at Non-Hodgkin's Lymphoma into human clinical trials. The company showed that their treatment eliminated all lymphocytes with a CD20 marker safely in primates. Why is CD20 important? CD20 is also the target of FDA approved drugs, Rituxan and Zevalin. InNexus are currently working with the FDA to outline the design of their clinical study on humans.

LymphomaInfo Social